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INTRODUCTION 
Lung cancer is the most frequently diagnosed major cancer in the world 
and most common cause of cancer related death. (1) Lung cancer is the most 
frequently diagnosed cancer and leading cause of cancer mortality in the world 
(1).  
       Previously, it was sufficient to diagnose primary lung carcinoma as 
either NSCLC or SCC for treatment purpose. With the development of new, 
successful treatments for adenocarcinoma, it is essential to diagnose the type of 
NSCLC whenever possible (1). 
       Routine sections stained with H&E remain the most common method by 
which lung cancers are classified; however typing of NSCLC and the more 
poorly differentiated tumours is often hard to achieve by H&E alone. 
Immunohistochemistry has emerged as a powerful, adjunctive tool for the 
differential diagnosis of lung carcinomas (1).  
       TTF-1 is a favoured marker for lung adenocarcinoma but has limited 
sensitivity and specificity. Napsin A is a functional aspartic proteinase that may 
be an alternative marker for primary lung ADC (1, 2). 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS & OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of napsin A in lung cancer tissues, 
compared with another marker, thyroid transcription factor-1 (TTF-
1), which has  already  recognized  as a useful marker for lung 
adenocarcinoma 
2. To compare the usefulness of napsin –A with TTF-1 for the 
identification of primary lung adenocarcinoma. 
3. To evaluate their utilization in the identification of primary and 
metastatic lung cancer. 
4. To evaluate the association of their expression with other 
clinicopathological parameters. 
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REVIEW OF LITERATURE 
ANATOMY(3):   
The lungs are the primary organs of respiratory function. Within the 
thoracic cavity, The lungs lie either side of the  mediastinum. Each lung is 
covered by a pleural cavity, which is formed by the visceral and parietal pleura. 
The lungs are roughly cone in shape. They have an apex, base, and three 
borders, three surfaces. The Left lung is slightly smaller than right  due to the 
presence of the heart. Hilum comprises a bronchus, two pulmonary veins, 
pulmonary artery, bronchial vessels, pulmonary plexus of nerves and lymphatic 
vessels. 
      Bronchial tree comprises Trachea - Right and Left Bronchus -  Lobar 
bronchi - Segmental   bronchi – Terminal bronchiole -  respiratory bronchiole – 
Alveoli. 
      The right lung comprises 3 lobes and 10 segments. 3 in the right upper 
lobe (apical, anterior, medial),2 in right middle lobe (medial and lateral), and 5 
in the  right  lower lobe (superior,  medial, anterior, lateral, posterior). 
The left lung comprises 2 lobes and 8 segments. 4 in the  left upper lobe 
(apicoposterior,  anterior, superior lingual, and inferior lingual) and 4 in the left 
lower lobe (superior, anteromedial, lateral, and  posterior).    
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HISTOLOGY (4):  
Lung parenchyma consists of airway (bronchi/bronchioles) and alveoli. 
The pulmonary lobule, (terminal respiratory unit) contains 3-5 terminal 
breonchioles, alveolar ducts and alveoli; It is the smallest anatomic unit. 
The entire respiratory tree is lined by pseudostratified, tall, columnar, 
ciliated epithelial cells with neuroendocrine cells, mucous secreating goblet 
cells in the wall of trachea and bronchi, basal cells, clara cells and 
inflammatory cells except vocal cord and alveoli. 
Alveoli is almost exclusively lined by type I and type II pneumocytes. 
Type I pneumocytes is 95% which is flattened, Type II is 5% which produces 
surfactant, and during repair, type II pneumocytes give rise to type I 
pneumocytes.  
Number of Clara cells increases towards terminal bronchiole, have 
secretory function. It is the  main progenitor cell after bronchiolar injury and 
have apical PAS + diastase resistant secretory granules. Neuro endocrine cells 
are numerous in neonatal bronchial and bronchiolar epithelium; in adults it is 
rare except as small clusters within epithelium of bronchi and bronchioles. 
Submucous glands comprises serous and mucus cells with myoepithelial lining 
and with age may have oncocytic change. 
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LUNG CANCER: 
The lung cancer is the uncontrolled abnormal growth of   cells which 
line the air passages(5). 
Lung cancer was first discovered in 1838 by A German pathologist  
named Johannes Muller. The association between lung cancer and smoking 
was demonstrated by a German doctor named Fritz Lickint  in 1929(5,6).  
Sir Richard Doll and Austin Hill published an article which confirmed 
the link between smoking and lung cancer (5, 6). 
EPIDEMIOLOGY:  
          In 2012 Lung cancer death constitutes around 1,590,000 persons and 
currently it is the leading cause of cancer death worldwide. The mortality rates 
vary across the world, and follow the smoking trends (7).  
          By region, there is the highest lung cancer mortality rates (per 100,000) 
in 2012 among males, were in Central and Eastern Asia (47.6) and Eastern 
Asia (44.8) and among females, in Northern America (23.5) and Northern 
Europe (19.1); the lowest rate were found in sub-saharan africa among  both 
males (4.4) and females (2.2)(7,8). 
          Depending on smoking prevalence, lung cancer mortality rate may be a 
mixture of decreasing, stable or increasing trends(6,7). 
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IN INDIA:  
 Lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all 
cancer related death (9, 10).  the highest incidences was reported  from Mizoram  
(8, 9, 10, 11). Delhi, Chennai and Bengaluru show a increasing trends of lung 
cancer. ( 8, 9 ).  
RECENT TREND IN INCIDENCE: 
 There has been a shift in the distribution of NSCLC over the past 4 
decades. Prior to the 1970s, squamous cell carcinoma was the most common 
histological type. However, after 1975, adenocarcinoma has been significantly 
increased and it remains the predominant subtype. (12, 13, 14) 
 Previously adeno carcinoma was thought to be confined to smokers.  
Recent studies showed that adenocarcinoma is not only confined to smokers 
but as occurs in non smokers as well, suggested that non-smoking related 
factors also plays a role in pathogenesis of adenocarcinoma.(13,14). 
AGE AND SEX:   
 The median age for a diagnosis of lung cancer is 72. More mommon in 
males with M:F- 2:1. Women tend to develop lung cancer 2 years earlier than 
men.  
ETIOLOGY AND PATHOGENESIS: 
 Smoking:  90% of all lung cancer results from tobacco exposure. The 
tobacco related products smoked in India are Bidi, Cigarettes, Hooka 
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and mixed. (15). Of which  Bidi is found to be more carcinogenic 
followed by Hooka.(16,17,18) 
 Passive smoking: Exposure to Environmental tobacco smoke during 
childhood is found to be strongly associated with increase risk.  
 Occupational risk:(20, 21)  Exposure to Asbestos, Arsenic, Nickel, 
Uranium, Chromium and rarely Acrylonitrite, berrylium, and dimethyl 
sulphate associated with lung cancer. 
 Genetics of lung cancer: (22, 23) The ras and myc family proto oncogene  
activation and tumor suppressor genes inactivation was found to be 
associate with lung cancer. 
 Dietary factors: β-carotene, Flavonoids, isothiocyanates  were found to 
have a protective role(24)   Smoking and Vitamin A deficiency, animal 
food products, dairy products  have a predisposing effect. (25-28).  
 Air pollution:(29- 36) Coal smoke, incense smoke and kerosene consists 
many carcinogens like SO2, CO, TSP, B(a)P, radon, thoron  also found 
to be associated with lung cancer development.   
 
CLINICAL PRRESENTATION:      
        The most common symptoms are   
 Cough 
 weight loss 
 Chest pain 
  increased sputum production 
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  hemoptysis   
 malaise  
 fever  
 Symptoms results from paraneoplastic manifestations.  
 
CLASSIFICATION OF LUNG CANCER:     
 WHO classification of Lung tumours 2015 is given in Annexure-  
 
           Lung cancer is divided into small cell cancer and non- small cell cancer 
(NSCLC). NSCLC accounts for 80% of all lung cancers and is comprised of 
Adenocarcinoma(ADC), Squamous cell carcinoma (SqCC), and large cell 
carcinoma. (2) Traditionally, it was enough to differentiate  small cell carcinoma 
from NSCLC, as NSCLC subtyping had not been shown to predict any 
differences in patient outcomes. Recent advances in molecular biology have led 
to an increase in target-specific chemotherapeutic therapies that require the 
subcategorization of NSCLCs.  
LUNG 
CARCINOMA
NON SMALL 
CELL
ADENO CA
SQUAMOUS
SMALL CELL
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The International Association for the study of Lung Cancer, the 
American Thoracic Society, and the European respiratory Society 
(IASLC/ATS/ERS) has outlined a new classification of lung ADCs based on a 
multidisciplinary approach. They have outlined the importance of further 
classifying NSCLCs as either ADCs or SqCCs, since ADCs should be tested 
for Epidermal growth Factor (EGFR) and Anaplastic Lymphoma Kinase 
(ALK) fusion gene mutations, as targeted chemotherapeutic agents can be used 
with greater efficacy(37).  
Lung adenocarcinomas are often associated with EGFR mutations, and 
can be effectively treated with tyrosine kinase inhibitors such as geftinib.(38,39). 
ADCs have been shown to have improved outcomes when compared to SqCCs, 
when treated with pemetrexed therapy, which inhibits specific enzymes in 
purine and pyramidine synthesis. Finally the distinction between ADCs and 
SqCCs can avoid potentially hazardous outcomes, as life threatening 
hemorrhages have been rarely reported when patients with SqCCs are treated 
with bevacizumab, a vascular endothelial growth factor inhibitor (40).  
NEW PATHOLOGIC CLASSIFICATION OF LUNG CANCER: 
 From 2004 WHO Classification, there is numerous important changes 
have been made in the 2015 World Health Organization Classification of 
Tumors of the Lung, Pleura, Thymus and Heart(41). The most significant 
changes are 
 Use of Immunohistochemistry  
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 Integration of molecular testing 
 New classification for small biopsies and cytology 
New Terminology and Criteria for Classification of Major Lung Cancer 
Types in Small Biopsies and Cytology: 
 In the previous 1967, 1981, and 1999 WHO classifications,  lung cancer 
s are classified mainly based  on resection specimens.(41,42,) Cytology was 
included for the first time in the 2004 WHO classification.  The percentage of 
NSCLC cases diagnosed as NSCLC-NOS has been as high as 30% to 
50%(43,44,45).  So far there  have been no established standardized criteria or 
terminology for the diagnosis of lung cancer in small biopsies or cytology. 
However, because of  the need for molecular testing and eligibility for specific 
therapies, now the situation has changed.  
In prior WHO classifications the diagnosis of lung cancer was mainly 
based on light microscopy.( 46, 47) Mucin is the only special stain recommended 
in the 1967 and 1981 WHO classification.First time  Immunohistochemistry 
was introduced  in the 1999 WHO classification for 3 main tumors:  
(1) large cell neuroendocrine carcinoma,  
(2) sarcomatoid carcinomas,  
(3) separation of malignant mesothelioma from carcinoma. 
 In the 2004 WHO classification in addition to these three tumors its 
usefulness was expanded  in the diagnosis of many other tumors as well.  
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Adenocarcinoma: 
 Adenocarcinomas are characterized by glandular differentiation by 
manifesting 1 or more architectural features. These are 
 lepidic 
 acinar 
  papillary, 
 Micropapillary 
 solid patterns.  
 The pattern has to mentioned in the report if it is present in the tumour.. 
Tumor cells may have homogenous basophilic cytoplasm, granular or foamy 
cytoplasm, often with cytoplasmic vacuoles The nuclei are eccentrically placed 
with fine granular chromatin to hyperchromatic nuclei. They may have 
macronucleoli. So finally, 
NSCLC with gland formations or mucin productions were classified as 
adenocarcinomas(41,46,47).  
Squamous cell carcinoma: 
Squamous differentiation is characterized by   3 morphologic features:  
 keratinization,  
 pearls,  
  intercellular bridges.  
 The cells have round to ovoid to elongated contours with sharply 
defined cell borders with dense cytoplasm. Cells with long cytoplasmic tails 
and ‘‘tadpole’’ configurations 
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may be seen. Nuclei are centrally situated and hyperchromatic with dense 
homogenous chromatin with pyknotic nuclei with inconspicuous nucleoli. So 
finally, 
The NSCLC with keratinization and intercellular bridges were classified 
as Squamous cell carcinoma(46,47). 
 The NSCLC that lacked these specific histological features were 
classified under waste basket category of Large cell carcinoma. Distinguishing 
small cell carcinoma from Non small cell carcinoma was important for 
planning treatment protocol. Until mid 2000s NSCLC subtyping was of less 
importance for determine treatment protocol. TTF-1 was introduced in routine 
practice in the early 2000s. In the absence of routine histological criteria, IHC 
was used to subtype NSCLCs in resected specimens(44,45).  
 The 2015 WHO classification revised this past approach. In this 
classification it is mandatory to differentiate Squamous cell Carcinoma from 
Adenocarcinoma both in resected as well as in small biopsies. Thus IHC is 
recommended for both resected and small biopsies in 2015 WHO 
classification.(41)  
 Because of the recent advances in cancer therapy, WHO 2015 propose 
to use IHC to further classify the cancers previously diagnosed as large cell 
carcinoma. When possible, it is essential to minimize the diagnosis of 
NSCLCs.(48,49) 
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 The large cell carcinoma category is reduced to those NSCLCs that 
cannot be classified as adenocarcinoma or squamous cell carcinoma by 
histology, mucin stain and IHC. It includes 
- Those large cell carcinoma with null IHC features. 
- Those large cell carcinoma with ambiguous IHC features. 
- Those large cell carcinoma with no IHC available.(49) 
 
 In 2015 WHO classification new criteria for the diagnosis of lung cancer 
based on small biopsy and cytology are introduced.(49)  
 Pathologic Features 
New Terminology and 
Diagnosis 
1. 
 
Morphologic adenocarcinoma patterns 
clearly present 
Adenocarcinoma (Describe 
identifiable patterns 
present) 
2. 
 
Morphologic adenocarcinoma patterns not 
present, but supported by special stains 
(TTF 1 positive) 
NSSLC favours 
adenocarcinoma 
3. 
 
Morphologic squamous cell patterns 
clearly present 
Squamous cell carcinoma 
4. 
 
Morphologic squamous cell pattern not  
present, but supported by special stains  
(p 63 or CK5/6 ) 
NSSLC favours Squamous 
Cell Carcinoma. 
5. No clear adenocarcinoma, squamous or 
neuroendocrine morphology or staining 
patterns 
NSCC NOS 
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If the malignancy is well differentiated one, it is easy to subtype the 
carcinoma either as ADCs or SqCCs. Well differentiated ADCs exhibits 
glandular formations where as well differentiated SqCCs exhibits Keratin pearl 
formation and intercellular bridging. If the tumor is poorly differentiated, 
making a definite diagnosis is not easy, even for experienced pathologists. If 
the classification of NSCLCs cannot be achieved with cytological/histological 
criteria alone, Immunohistochemistry (IHC) should be employed(49).  
With the use of relatively specific marker, Thyroid Transcription Factor-
1 (TTF-1), lung primary can be separated from a metastasis in certain extent. 
Another lung specific marker is napsin a ( Nap-A), that complements TTF-1 in 
identifying a primary lung carcinoma, also helpful in subtyping NSCLC, and 
helps to distinguish NSCLC, particularly poorly differentiated adenocarcinoma, 
from small cell carcinoma(SCC)(1,42).  
Without the use of immunohistochemistry markers, it is difficult to 
subtype a lung cancer on small biopsies that may not show differentiation 
because of poor sampling, small amount of tumor tissue, crush artifact or cell 
dispersals(43,44). In that situation we can use panel of IHC markers to subtype. 
The basic panel should include atleast one marker specific for adenocarcinoma 
and one specific marker for squamous cell carcinoma. The commonly used 
basic panel of markers for subtyping includes TTF 1, P63 and CK 5/6.  In most 
of the cases these basic panel of markers are enough for subcategorization.  
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TTF-1: 
TTF-1 also called as thyroid specific enhancer binding protein. It 
regulates transcription activity of thyroid, lung (surfactant proteins A, B and C, 
Clara cell secretory protein) and diencephalon specific genes(51,52). It is positive 
in normal lung type II pneumocytes and clara cells, thyroid follicular and 
parafollicular C cells. It is a nuclear marker. TTF-1 is positive in lung 
carcinoma (small cell - 90 %, adenocarcinoma – 75%, large cell – 40 %, 
Squamous cell – 5 %. Also expressed in hyperplastic and neoplastic thyroid 
tissue, but less common in undifferentiated thyroid carcinomas(53,54). Other 
tumours positive for TTF-1 includes primary thyroid cancers and small cell 
carcinoma of various organs. TTF1 regulates the cell proliferation and new 
vessels formation, thereby promotes the cancerisation(51,52,53,54). 
NAPSIN A: 
Napsin is an aspartic proteinase of the pepsin family involved in the 
maturation of surfactant protein B. It is found primarily in lung and kidney(51).  
•TTF-1, NAPSIN A
ADENO 
CARCINOMA
•P63
•CK 5/6
SQUAMOUS 
CELL 
CARCINOMA
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It is expressed in type 2 pneumocytes, alveolar macrophages, renal tubules and 
exocrine glands and ducts in the pancreas(42, 55,56). It is cytoplasmic marker. It is 
useful as an individual marker or as a part of panel to distinguish lung 
adenocarcinoma from squamous cell carcinoma.  Also useful in identifying 
metastatic disease with unknown primary as originating in lung(42,50). It is 
superior to TTF 1 in distinguishing metastatic pulmonary from non pulmonary 
adenocarcinoma in cell blocks of pleual fluid and in distinguishing primary 
lung adenocarcinoma from other carcinomas particularly primary lung small 
cell carcinoma and primary thyroid carcinoma(50, 55,56,57,58). 
P63:  
P63 is a recently discovered marker of p53 family involved in 
development of epithelial tissues(49). Normally P63 is expressed in bronchial 
reserve cells and metaplastic squamous epithelial cells. It is a nuclear 
marker(49). P63 is consistently expressed in SqCC in the lung. But it is also 
expressed in a subset of adenocarcinoma and large cell carcinomas but with 
weak low level of positivity. A cut-off value of  >10% tumour cell positivity is 
taken for categorization of squamous cell carcinoma(49). 
Cytokeratin 5/6: 
Cytokeratin 5/6 is a sensitive marker for squamous differentiation. 
Ck5/6 is normally expressed in basel cell of bronchial epithelium. CK5/6 
positivity is cytoplasmic. It is mainly used to distinguishing mesothelioma from 
pulmonary adenocarcinoma(49). 
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P40: 
  P40 is a more specific marker than P63 for squamous cell carcinoma. 
Because it shows  virtually no overlap in adenocarcinoma. Hence this p40 may 
replace p63 as the best immunohistochemical squamous marker.(49,59,60) 
Although p63 frequently show nuclear positivity in most of squamous 
cell carcinomas, it may show patchy or weak staining in 20% to 30% of 
adenocarcinomas. This immunophenotype actually indiacates the good 
prognosis adenocarcinoma. But usually it has been misinterpreted as squamous 
differentiation.(61,62) 
To preserve the tissue for molecular studies, only limited initial panel of 
one adeno and one squamous marker shold be used. Or else we can use cocktail 
of one nuclear and one cytoplasmic marker (TTF1/Cytokeratin 5/6). (49) 
 
Application of Immunohistochemistry in lung pathology: 
 Whenever we deals with lung small biopsies we have to go in a 
systematic stepwise manner. 
1. We have differentiate lung primary from secondary tumours 
2. Within the lung primary whether it is neuroendocrine or non 
neuroendocrine 
3. Distinguishing Adenocarcinoma from Squamous cell carcinoma 
4. Distinguishing pulmonary malignancy from pleural malignancies. 
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NEUROENDORINE VS NON NEUROENDOCRINE NEOPLASM 
IHC is helpful for confirmation of neuroendocrine differentiation. But 
its utility is limited for separating individual NeuroEndocrine Tumour from 
each other. Upto 20% of NSCLCs show positivity for Neuro Endocrine  
markers. 
LARGE CELL NEUROENDOCRINE CARCINOMA: 
The diagnosis of large cell NEC shouldnot be made without the IHC 
profile. 
• Large cell carcinoma with NE architecture without NE staining is 
categorized as LARGE CELL CARCINOMA WITH 
NEUROENDOCRINE ARCHITECTURE 
Primary Vs 
Secondary
Neuroendorine Vs 
Non 
neuroendocrine
Adeno Vs 
Squamous
Pulmonary Vs 
Pleural
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• Large cell carcinoma with NE staining without NE architecture is 
categorised as LARGE CELL CARCINOMA WITH 
NEUROENDOCRINE DIFFERENTIATION  
 
ADENOCARCINOMA VS SQUAMOUS CELL CARCINOMA: 
Based on the typical morphological features they should be differentiate 
from each other. 
 
Squamous Cell carcinoma histological features: 
   
Adenocarcinoma histological features: 
 
  
LUNG 
CARCINOMA
NON SMALL 
CELL
ADENO CA
SQUAMOUS
SMALL CELL
Keratinization  
Keratin pearls 
Intercellular bridges  
Glandular differentiation 
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JUDICIOUS USE OF IMMUNOHISTOCHEMICAL STAINS:  
        
Usually as a basic panel TTF1 for adenocarcinoma and either P63 or 
CK5/6 for SqCCA is used in most of the laboratories. With the use of these 
markers we can get four different immunohistochemical profile(49). 
 TTF1 Positive & P63 Negative 
(Positive adeno marker with Negative Squamous marker) 
 TTF1 Negative & P63 Positive 
(Negative adenomarker with positive squamous marker) 
 TTF1 Positive & P63 Positive 
(Adeno and squamous marker - both positive) 
 TTF1 Negative & P63 Negative 
(Adeno and squamous marker – both negative) 
 
 
TTF1/P63
+/ +
- / +
- / -
+ / -
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INTERPRETATION OF TTF1 & P63 PROFILE:I 
 Cases positive for an adeno marker with a negative squamous 
marker: 
 should be classified as NSCLC, favor adenocarcinoma (49)  
 
 Cases positive for a squamous marker, with a negative adeno 
marker 
           should be classified as NSCLC, favor squamous cell carcinoma, And  
           with the above impression, a comment should be mentioned to specify  
           whether the differentiation was detected by light microscopy and/or by  
            special stains.  
  
These 2 markers are generally mutually exclusive.(44,49)  
  
 Cases positive for both adeno and squamous markers  
In these cases first we have to assess whether these two markers 
were expressed by same population of tumor cells or different 
population of tumor cells. 
If positive in same tumor population, despite any expression of 
squamous marker, if the tumor is positive for TTF1 it should be 
ckassified as NSCLC favours adenocarcinoma.(44,49,59,63,64) 
If TTF-1 reactivity is present in one population of tumor cells and 
another population is positive for squamous markers, this may raise the 
possibility of adenosquamous carcinoma(49,64,65,66,67,68). To classify the 
tumour under adenosquamous category, the tumour should contain 
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atleast 10 % of each component. This quantification can be done only in 
resected specimens. So the diagnosis of adenosquamous carcinoma 
should not be made in the small biopsy specimens(49.69).  
 
 Cases negative for both adeno and squamous markers: 
For these case, it should proceeded with cytokeratin stain to 
confirm the histiogenis of the tumor whether it is a carcinoma or not. If a 
keratin stain is negative, it excludes carcinoma. So other tumors 
exhibiting epithelioid morphology, such as melanoma,lymphoma, 
malignant mesothelioma, or epithelioid hemangioendothelioma has to be 
considered. To exclude this S100, CD45, or CD31 may be used.(49,70)  
TTF 1 negativity rules out the primary lung adenocarcinomas. In 
these cases metastasis from colon and breast has to be considered. To 
exclude these primary origin, CDX-2, cytokeratin 20, estrogen receptor, 
or progesterone receptor expression may be needed. Thoroug clinical 
evaluation to exclude a metastasis from other sites should be done(49,71).  
TTF-1 positivity and CDX2 negativity may be seen in Invasive 
mucinous adenocarcinomas or colloid adenocarcinomas. So clinical 
correlation is needed in such tumors to exclude a metastasis from other 
sites such as the pancreas or colon.(49,71) 
 
 Algorithm for Subclassification of Poorly Differentiated Non-small Cell 
Lung Carcinomas Using Immunohistochemical Staining in Lung Biopsies (69) 
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TTF1 P63 CK5/6 DIAGNOSIS 
+ + - Adenocarcinoma 
- + / - + Squamous cell carcinoma 
- 
Diffusely 
positive 
- Squamous cell carcinoma 
- Focally positive - Poorly differentiated NSCLC NOS 
- - - Poorly differentiated NSCLC NOS 
 
METASTASES TO THE LUNGS 
Metastatic malignant neoplasms are the most common form of 
secondary lung tumours.(72,73,77) Lung metastasesae identified in 30- 55 % of all 
cancer patients  Almost any cancer has propensity to spread to the lungs, but 
most common tumours are 
Bladder cancer 
Colon cancer 
Breast cancer 
Prostate Cancer 
Renal cancer 
Primary lung cancers mostly metastasize to the adrenal glands, liver, 
brain and bone. 
Benign Cancers Metastasizing to Lung: (74,75,76,77) 
Leiomyoma 
Meningioma 
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Thymoma 
Giant Cell tumour of bone 
 
MECHANISM OF CANCERS SPREAD  TO LUNG: (72,73,74) 
 
 
 
 Metastatics can be either due to direct or contiguous extension  or true 
metastatic spread via blood vessels, lymphatic route or along the airway. 
 
DISTINGUISHING A PRIMARY LESION FROM A  METASTASIS TO 
THE LUNG:  
 It may be difficult on the basis of morphology alone, and need a 
multidisciplinary approach (72, 73, and 77).   
Metastasis
Direct extension
From thyroid 
esophagus,thymus
and chest wall
True metastatic 
spread
1. Hematogenous
2.Airway
3. Lymphatic
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Clinical Presentation & Image findings:  
 Multiple  bilateral peripheral nodules.(Classical) 
 As a solitary coin lesion (Rare - 9% of cases) (73, 77). 
 Endobronchial metastasis simulating primary bronchogenic carcinoma ( 
unusual ) 
 Milliary spreads of microscopic tumor nodules simulate an infectious 
process.  
 Growth along the alveolar walls,simulates a primary bronchioloalveolar 
carcinoma –lung. 
To rule out the other primaries also certain organ specific IHC markers 
can be used. CK7/ CK20 panel is primarily used for distinguishing metastasis 
from primary in every organ. Lung cancers mainly have the profile of CK7 
positive CK20 Negative. But in the lung by using this CK7 / CK 20 panel, we 
cannot rule out malignancies metastasizing from certain primaries. (78)  
MDA
Clinical 
History
Image 
findings
Careful 
scrutiny of  
history
Special 
technique
26 
 
By using CK7/CK20 panel we can exclude Metastasis from prostate, 
kidney and ovary. 
 In addition to lung primary, colon, breast and ovary have similar CK7 
Positive / CK 20 Negative profile.  
 
PRIMARY CK7 CK20 
Lung Positive Negative 
Ovary Positive Negative 
Colon Positive Negative 
Breast Positive Negative 
 
 But organ specific antibodies can be used to exclude theses primaries.  
 For breast cancers ER and GCDFP can be used.  
 For Ovary ER, inhibin can be used.  
 For adrenal tumors Inhibin is a specific marker.  
 For prostate PSA is used.  
And in all of these primaries TTF1 is negative except in primary 
from thyroid malignancies. But napsin will be negative in primary from 
thyroid (77, 78).   
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SIMPLIFIED PANEL FOR DISTINGUISHING PRIMARY FROM 
SECONDARY: 
 
Organ TTF1 CK7 CK20 ER PSA GCDFP INHB CD10 RCC 
Lung + + - - - - - - - 
Colon - + - - - - - - - 
Breast - + - + - + - - - 
Prostate - - - - + - - - - 
Kidney - - - - - - - + ++ 
Adrenal - - - - - - + - - 
Ovary - + - + - - + - - 
 
PLEURAL TUMORS VERSUS PRIMARY LUNG TUMOURS: 
Lung cancers especially those located peripherally can simulate 
mesothelioma radilogically as well as in some occasions histopathologically. 
So IHC can be used to distinguishing these mesothelioma from primary 
adenocarcinoma lung (79, 80). 
  IHC markers to differentiate Pleural versus primary lung AdCC(81,82): 
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MESOTHELIOMA ADENOCARCINOMA LUNG 
 
CK 5/6 
Calretinin  
Mesothelin  
WT1 
Podoplanin  
 
TTF 1 
CEA 
CD15 
MOC 31  
 
  
MULTIDISCIPLINARY APPROACH FOR LUNG CANCER 
DIAGNOSIS: 
Multidisciplinary approach is needed for diagnosing lung cancers. The 
new concepts  in IASLC / ATS / ERS classification are the direct result of the 
multidisciplinary approach,which includes clinicians, molecular biologists, 
radiologists, surgeons and pathologist. To achieve a corresct diagnosis and 
management all specialists need to work together. 
 Each institution must have a multidisciplinary strategy that addresses  
1. how to best obtain these small specimens, 
2. how to process them in the pathology laboratory,  
3. how to preserve material for molecular testing,  
4. how to send specimens to the molecular laboratory for expedited testing 
5. how to report the results in a pathology report.  
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It is useful to have a multidisciplinary committee to develop this strategy 
and to keep lines of communication open in order to monitor issues as they 
arise in an ongoing fashion. Pathologists should take a leadership role in this 
process. 
 
 
 
PERSONALIZED MEDICINE IN LUNG CANCER : 
The pathologist’s role in diagnosing lung cancers is becoming more 
important, because lung cancer therapy is becoming personalized for individual 
patients nowadays (49). 
Therapy is based on 
1. the histologic cell type and subtypes of lung cancer (adenocarcinoma 
versus squamous 
2. molecular status  
 epidermal growth factor receptor [EGFR] mutation 
Clinician
Radiologist
SurgeonPathologist
Molecular 
biologist
MULTIDISCIPLINARY 
APPROACH TEAM 
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 anaplastic lymphoma kinase [ALK] rearrangement in 
adenocarcinoma 
 
Understanding this concept is essential for the pathologists. 
Since the 2004 WHO classification, there have been 4 therapeutic 
advances for non–small cell lung carcinoma (NSCLC)(49).  The first relates to 
1. Tyrosine kinase inhibitors as first-line therapy in patients with 
advanced lung adenocarcinoma with EGFR mutations.(83–87) 
2.  Adenocarcinomas with ALK rearrangements are responsive to 
crizotinib.(84–90)  
3.  Adenocarcinoma or NSCLC, not otherwise specified (NSCLC-
NOS), are more responsive to pemetrexed than those squamous cell 
carcinoma.(91-93) 
4.  Squamous cell carcinoma is associated with life-threatening 
hemorrhage in patients treated with bevacizumab.(93,94) 
 
 
 
 
 
 
MATERIALS & METHODS 
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MATERIALS AND METHODS 
The present study is a both prospective and retrospective study of lung 
carcinomas conducted in the Institute of Pathology, Madras Medical College & 
Rajiv Gandhi Government General Hospital, Chennai, during the period 
between September 2016 to July 2017. 
A total of 22285 specimens sent to the Department of pathology during 
the period of September 2015 to August 2017 for histopathological 
examination. 
Out of that 309 cases were lung specimens. Among them 50 malignant 
cases selected for this study. 
Source of data: 
The Lung carcinoma cases reported in the institute of Pathology, Madras 
Medical College and Rajiv Gandhi Government General Hospital from 
September 2015 to August 2017 which have been sent by the Department of 
surgical oncology and Department of Thoracic Medicine. 
Inclusion criteria:  
• Histopathological slides of biopsy proven malignant cases in which 
histological typing cannot be done by routine H&E sections alone.  
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Exclusion criteria:  
 Histopathological slides of biopsy proven malignant cases in which 
histological typing can be done in routine H&E sections itself.  
 Histopathological slides of biopsy proven non neoplastic lung lesions 
 Malignancies other than epithelial tumours 
 Cases with inadequate material 
Method of data collection: 
           Detailed history of the cases regarding age, gender, clinical presentation, 
smoking history, image findings were obtained for all the cases of lung cancers 
reported during the period of study from the histopathology records. 
Hematoxylin and Eosin stained 4 micron thick sections of the paraffin 
tissue blocks of the specimens were reviewed. Along with 
immunohistochemistry slides which were done for subtyping of lung 
carcinomas were reviewed. The markers used in our department for subtyping 
were TTF1 for adenocarcinoma, P63 or CK5/6 for squamous cell carcinoma 
and Any of the neuroendocrine markers( Synaptophysin, Chromogranin or, 
NSE) were used. That slides were taken from the department and reviewed. 
 50 cases were selected randomly from the total cases and their 
representative formalin fixed paraffin embedded tissue samples were subjected 
to immunohistochemistry with a marker Napsin A.  
The results were recorded with photographs. 
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Histological Review: 
          The histopathological diagnosis and its subtyping based on morphology 
alone was made by the senior pathologist in almost all cases. 
          Histopathological diagnosis was done according to the recent WHO 
terminology for lung carcinomas in small biopsy specimens. 
Immunohistochemical evaluation: 
 Immunohistochemical analysis of marker for Napsin a was done in 
paraffin tissue blocks using super sensitive HRP polymer system based on non 
bioton polymeric technology.Sections with a thickness of 4 microns were cut 
from the paraffin tissue blocks. They were transferred to gelatin coated slides. 
Heat induced antigen retrieval was done. The antigen was bound with rabbit 
monoclonal antibody (PATHNSITU) against Napsin and then the addition of 
secondary antibody conjugated with horse raddish peroxidase – polymer and 
diaminobenzidine substrate. 
ANTIBODY FOR IHC: 
Antigen Vendor Species(clone) Dilution Positivity 
Positive 
control 
Napsin Pathnnsitu 
Rabbit 
monoclonal 
EP205 
Ready to 
use 
Cytoplasmic 
positivity 
Lung – type 2 
pneumocytes 
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The step by step procedure of IHC is listed below in detail. 
PREPARATION OF SLIDES: 
1. 4μ thick sections were cut from formalin fixed paraffin embedded 
tissue samples and transferred to charged slides 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 10 minutes x 2 
changes. 
4. The sections were dehydrated with absolute alcohol for 10 minutes x 
2 changes. 
5. The slides were then immersed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 2 minutes x 2 
changes. 
ANTIGEN RETRIEVAL: 
7.  Antigen retrieval was done with microwave oven in appropriate 
temperature with    appropriate buffer for 20 to 25 minutes. 
8.  The slides were cooled to room temperature and washed in running 
tap water for 5  minutes.  
9.  Apply peroxidase block over the sections for 10 minutes. 
10.  Wash the slides in wash buffer for 5 minutes x 2 changes. 
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ANTIBODY APPLICATION: 
11. The sections were drained (without washing) and appropriate 
primary antibody was applied over the sections and incubated for 1 
hour. 
12. The slides were washed in wash  buffer for 5 minutes x 2 changes. 
13. The slides were covered with CRF Anti – Polyvalent HRP Polymer 
for 30 minutes. 
14. The slides were washed in wwash buffer for 5 minutes x 2 changes. 
CHROMOGEN APPLICATION: 
15. DAB substrate was prepared by diluting 1 drop of DAB chromogen 
to 1 ml of DAB buffer. 
16. DAB substrate solution was applied on the sections for 5 minutes. 
17. The slides were washed well in distilled water for 5 minutes. 
18. The sections were counterstained with Hematoxylin stain for 2 
seconds (1 dip). 
19. The slides were washed in running tap water for 3 minutes. 
20. The slides are air dried, cleared with xylene and mounted with 
DPX. 
CONTROLS: 
Normal type 2 pneumocytes were taken as internal control for assessing 
Napsin A reactivity and to avoid false negative results. 
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INTERPRETATION AND SCORING SYSTEM: 
 The immunohistochemically stained slides were analysed for the 
presence of reaction, cellular localization (nuclear / cytoplasmic/ membranous), 
percentage of stained slides and intensity of reaction. 
 Proportion Score: This study was done in small biopsy specimens. IHC 
staining was evaluated without exact quantification. 
• Negative: No reactivity 
• Focal     : Labelling in the minority of cells 
• Diffuse  : Labelling in the majority of cells 
Intensity Score: 
• 0 – Negative 
• 1 – weak  
• 2 – intermediate 
• 3 – strong  
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STATISTICAL ANALYSIS 
 The statistical analysis is peformed using IBM statistical package for 
social science software (SPSS) version 20. The correlation of 
clinicopathological parameters and comparison of napsin A expression with 
TTF1 expression was calculated by Pearson Chi Square test and P value less 
than 0.05 are considered statistically significant. 
  
OBSERVATIONS & RESULTS 
 
 
 
 
 
 
38 
 
OBSERVATION AND RESULTS 
          The total number of lung specimens received in our institute was 309  
over a period of september 2015 to august 2017 Of which non neoplastic cases 
were 201. Malignant cases were 108. Out of 108 malignant cases, 36 cases 
were diagnosed and subtyped with only light microscopy without the use of 
immunohistochemistry. For rest of the cases, because of the lack of typical 
specific features of subtypes, we proceeded with IHC markers of TTF1, CK5/6, 
P63, NSE, Synaptophysin, Chromagranin.  With these markers subtyping was 
done.  From that cases 50 cases were randomly chosen for this study.  
TABLE 1: FREQUENCY OF LUNG CARCINOMA CATEGORIES 
Diagnosis Frequency Percent 
ADCC 23 46.0 
SCC 7 14.0 
SQCC 20 40.0 
Total 50 100.0 
 
TABLE - 1 
  
 
46%
14%
40%
Diagnosis
ADCC
SCC
SQCC
CHART - 1 
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It was found that adenocarcinoma had a maximum incidence of 46%. 
The second most common was squamous cell carcinoma accounting for 40%. 
Small cell carcinoma was the third most frequent subtype with relative 
percentage of 14% of the total cases.  
 
TABLE 2: AGE WISE DISTRIBUTION OF TUMORS 
Age range Number of cases Percentage (%) 
41-50 years 7 14% 
51-60 years 19 38% 
61-70 years 17 34% 
71-80 years 7 14% 
 
TABLE - 2 
 
 
 
14%
38%
34%
14%
41-50 years 51-60 years 61-70 years 71-80 years
CHART - 2 
40 
 
It is inferred from the above table and bar diagram that there is no 
increase in the incidence of lung cancers with increasing age. The tumour 
seems to be distributed along the age group in no specific pattern. 
The peak incidence was noted in a age group of 51 to 60 years, the 
number of patients were 19 accounting for 38% of cases. It seems to have a 
least incidencein the age group of  41 to 50 years and 71 to 80 years with 
relative percentage of 14%.  
 
TABLE 3: THE AGE WISE DISTRIBUTION OF DIFFERENT TYPES 
OF LUNG CANCERS 
 
 Diagnosis Total 
ADCC SCC SQCC 
Age_range 
40-50 
Count 4 0 3 7 
% within Diagnosis 17.4% 0.0% 15.0% 14.0% 
51-60 
Count 10 2 7 19 
% within Diagnosis 43.5% 28.6% 35.0% 38.0% 
61-70 
Count 7 3 7 17 
% within Diagnosis 30.4% 42.9% 35.0% 34.0% 
71-80 
Count 2 2 3 7 
% within Diagnosis 8.7% 28.6% 15.0% 14.0% 
Total 
Count 23 7 20 50 
% within Diagnosis 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.366 P=0.762 
 
TABLE - 3 
41 
 
 
 
 
Table 3 shows the percentage of individual subtypes in different age 
groups. The purpose of this table is to look for any specific age predeliction by 
different subtypes of tumors. 
 It was inferred from the table 3 that adenocarcinoma was most common 
in the age group of 51 to 60 years accounting for  43.5% (10cases). It was least 
common in the age group of 71 to 80 years accounting for 8.7% (2 cases).  
 Squamous cell carcinoma was most common in the age group of 51 to 
60 years and 61 to 70 years with relative range of 35% in each group.(7 cases). 
It was least common in the age group of 41 to 50 years and 71 to 80 years with 
relative range of 15% in each group. (3 cases) 
 Small cell carcinoma was most common in the age group of 61 to 70 
years accounting for 42.9% (3 cases), followed by second most commonly seen 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ADCC
SCC
SQCC
17%
0% 15%
44%
29%
35%
30%
43%
35%
9%
29%
15%
71-80
61-70
51-60
40-50
CHART - 3 
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in 51 to 60 years and 71 to 80 years with relative range of 28.6% in each age 
group. (2 cases) 
 Hence adenocarcinoma and squamous cell carcinoma was found to be 
commonly affect the age group of 51 to 60 years. Small cell carcinoma was 
found to be common in slightly older age group of 61 to 70 years. 
 
TABLE 4: GENDER WISE DISTRIBUTION OF TUMOURS: 
Gender Number of cases Percentage 
Male 35 70% 
Female 15 30% 
 
Pearson Chi-Square=3.913 P=0.141 
 
 
 
 
 
Male
70%
Female
30%
TABLE - 4 
CHART - 4 
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The incidence of lung cancers in males was found to be 70% (35 cases). 
The incidence of lung cancers in female was found to be 30%(15 cases). Male 
to female ratio was 2.3:1. P value is 0.141. So gender has significant value in 
lung cancers. 
 
TABLE 5: DISTRIBUTION OF DIFFERENT SUBTYPES OF CANCERS 
AMONG MALES AND FEMALES. 
 
Diagnosis 
Total 
ADCC SCC SQCC 
SEX 
MALE 
Count 14 7 14 35 
% within 
Diagnosis 
60.9% 100.0% 70.0% 70.0% 
FEMA
LE 
Count 9 0 6 15 
% within 
Diagnosis 
39.1% 0.0% 30.0% 30.0% 
Total 
Count 23 7 20 50 
% within 
Diagnosis 
100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.913 P=0.141 
 
  
TABLE - 5 
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It has been inferred from the table 6 that adenocarcinoma was common 
among males with relative percentage of 60.9% (14 cases) as compared to 
39.1%(9 cases) in females. 
 Squamous cell carcinoma was common among males with relative 
percentage of 70%(14 cases) as compared to 30%(6 cases) in females. 
 Small cell carcinoma was found to be exclusively occurred only in 
males with relative percentage of 100.0%(7 / 7 cases). 
  
0%
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100%
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39%
0%
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TABLE 6: SIDE DISTRIBUTION IN LUNG CANCERS 
Side Number of cases Percentage 
Left 22 44% 
Right 28 56% 
 
 
 
 
 
From the above table it was inferrred that lung cancers found to be occur 
more commonly in Right lobe with relative percentage of 56% followed by left 
lobe with little less frequency of 44%. 
 
 
 
 
Left
44%
Right
56%
TABLE - 6 
CHART - 6 
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TABLE 7: INVOLVEMENT OF DIFFERENT LOBES IN LUNG 
CANCERS 
Lobe Number of cases Percentage 
Upper 33 66% 
Middle 5 10% 
Lower 12 24% 
 
 
            
 
 
 
The above table shows that lung cancers seems to be predominant in 
upper lobe with relatively higher percentage of 66% (33 / 50 cases), followed 
by lower lobes found to be involved in 24% of cases with least common in 
moddle lobe with least percentage of 10%. 
 
Upper Middle Lower
66%
10%
24%
TABLE - 7 
CHART - 7 
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TABLE 8: CLINICAL FEATURES IN LUNG CANCER 
Symptoms Number of cases Percentage 
Chest pain 10 20% 
Cough 13 26% 
Dyspnoea 9 18% 
Hemoptysis 9 18% 
No symptom 9 18% 
 
 
 
 
Table 8 showed  the commonest symptoms in lung cancer patients. 
Among these five symptoms, most of the patients(26%) presented with the 
symptom of cough followed by chest pain in 20% of patients, followed by 18% 
of patients with dyspnoea, 18% with hemoptysis and 18% of patients presented 
with no specific symptoms. 
Chest pain Cough Dyspnoea Hemoptysis No symptom
20%
26%
18% 18% 18%
TABLE - 8 
CHART - 8 
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TABLE 9: COMMON SYMPTOMS IN EACH LUNG CANCER 
SUBTYPE 
Symptoms 
 Diagnosis Total 
ADCC SCC SQCC 
Symptom
s 
chest pain 
Count 5 1 4 10 
% within Diagnosis 21.7% 14.3% 20.0% 20.0% 
Cough 
Count 6 4 3 13 
% within Diagnosis 26.1% 57.1% 15.0% 26.0% 
Dyspnoea 
Count 4 0 5 9 
% within Diagnosis 17.4% 0.0% 25.0% 18.0% 
hemoptysis 
Count 4 1 4 9 
% within Diagnosis 17.4% 14.3% 20.0% 18.0% 
No symp 
Count 4 1 4 9 
% within Diagnosis 17.4% 14.3% 20.0% 18.0% 
Total 
Count 23 7 20 50 
% within Diagnosis 100.0% 
100.0
% 
100.0% 100.0% 
Pearson Chi-Square=5.706 p=0.680 
 
 
 
 
TABLE - 9 
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Table 9 showed commonest presentation in each lung cancer subtype. In 
lung adenocarcinoma cough followed by chest pain was found to be 
commonest presentation with relative percentage of 26.1% and 21.7% 
respectively. 
Among the squamous cell carcinoma patients, Dyspnoea is the 
commonest presenting complaints with 25% relative percentage. 
Among the small cell carcinoma patients cough is the predominant 
symptoms with relative percentage of 57.1%. 
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TABLE 10: SMOKING HISTORY IN LUNG CANCER PATIENTS. 
 
 
 
 
 
 
 
It was inferred from table 10 that lung cancers were common in smokers 
with 62% accounting for 31 cases out of 50 cases. 38% of non smokers 
developed lung cancers accounting for 19 out of 50 cases. 
 
 
62%
38%
Smoking
Present Absent
Smoking history Number of cases Percentage 
Present 31 62% 
Absent 19 38% 
CHART - 10 
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TABLE 11: SMOKING HISTORY IN LUNG CANCER SUBTYPES 
 Diagnosis Total 
ADCC SCC SQCC 
Smoking 
NO 
Count 12 0 7 19 
% within 
Diagnosis 
52.2% 0.0% 35.0% 38.0% 
YES 
Count 11 7 13 31 
% within 
Diagnosis 
47.8% 100.0% 65.0% 62.0% 
Total 
Count 23 7 20 50 
% within 
Diagnosis 
100.0% 100.0% 100.0% 100.0% 
        Pearson Chi-Square=6.328* p=0.042 
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Table 11 showed that adenocarcinoma seems to be commonly occurs  in 
non smokers with relative percentage of 52.2% (12 cases) in contrast to 47.8% 
in smokers (11 cases).  
Squamous cell carcinoma and small cell carcinoma seems to be common 
in smokers with relative percentage of 65% (13 cases) and 100.0% (7 cases) 
respectively.Small cell carcinoma was found to be occur exclusively only in 
smokers. 
 
TABLE 12: IMAGE FINDINGS IN LUNG CANCER PATIENTS 
Imaging findings Number of cases Percentage 
Consolidation 8 16% 
Collapse 12 24% 
Mass 27 54% 
Pleural effusion 3 6% 
 
 
 
 
16%
24%
54%
6%
Consolidation Collapse Mass Pleural effusion
CHART - 12 
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 From the above table, most common image findings in lung cancers 
was found to be lung mass with relatively highest percentage of 54% followed 
by collapse with 24% followed by consolidation with 16% and least common 
finding was pleural effusion with relative frequency of 6%. 
 
IMMUNOHISTOCHEMICAL EXAMINATION OF LUNG CANCERS:  
The expression of TTF1 and Napsin A was studied in different subtypes 
of lung carcinomas. A subset of 50 cases were selected randomly that 
constituting cases in which definitive histopathological diagnosis could not be 
made out by using light microscopy alone and those cases in which IHC was 
done and final definitive diagnosis was made out. 
 
TABLE 13: HISTOPATHOLOGICAL DIAGNOSIS IN SELECTED 
CASES: 
HPE diagnosis Number of cases Percentage 
AdCC 10 20% 
SqCC 6 12% 
SCC 3 6% 
NSCLC 16 32% 
Positive for malignancy 15 30% 
 
 TABLE -13 
54 
 
 
 
 
 
From the above table it was inferred that in 32% of cases definite 
subtyping couldnot be done by histomorphological examination, they were 
diagnosed as NSCLC. In around 30 % of cases, diagnosis was given as positive 
for malignancy by using light microscopy alone. For rest of the cases to some 
extent diagnosis was made light microscopically which constituting 20%(10 
cases) of   cases diagnosed as adenocarcinoma, 12%(6 cases) of cases 
diagnosed as squamous cell carcinoma and 6%(3 cases) of cases diagnosed as 
small cell carcinoma. 
For these cases TTF1 which was a well known already proven marker 
for adenocarcinoma of lung was performed to categorise adenocarcinoma. In 
addition to TTF1, whenever needed, squamous cell markers either CK5/6 or 
P63 was performed for confirmation of squamous cell carcinoma. Some cases 
in which even after the application of TTF1, CK5/6 or P63, neuroendocrine 
20%
12%
6%
32%
30%
AdCC SqCC SCC NSCLC Positive for malignancy
CHART - 13 
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markers (chromogranin, synaptophysin, NSE) were performed to diagnose 
small cell carcinoma. 
In these cases, formalin fixed paraffin embedded sections were 
subjected to immunohistochemical analysis with Napsin A. The results were 
evaluated for both TTF1 and Napsin A in all cases and have been tabulated in 
the following tables and illustrated by tables also. 
 
TABLE:14: FREQUENCY OF TTF I EXPRESSION IN LUNG 
CANCERS 
 
TTF Frequency Percent 
NEGATIVE 24 48.0 
POSITIVE 26 52.0 
Total 50 100.0 
 
 
 
 
 
48%
52%
TTF
NEGATIVE
POSITIVE
TABLE – XIV 
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From the above table, it was inferred that TTF1 was positive in totally 
52% of cases (26 cases) and negative in 48% (24 cases) of cases. 
TABLE:15: FREQUENCY OF TTF1 EXPRESSION IN DIFFERENT 
SUBTYPES OF LUNG CANCERS: 
 TTF Total 
NEGATIVE POSITIVE 
Diagnosis 
ADCC 
Count 0 23 23 
% within TTF 0.0% 88.5% 46.0% 
SCC 
Count 4 3 7 
% within TTF 16.7% 11.5% 14.0% 
SQCC 
Count 20 0 20 
% within TTF 83.3% 0.0% 40.0% 
Total 
Count 24 26 50 
% within TTF 100.0% 100.0% 100.0% 
     
Pearson Chi-Square=43.132** p<0.001 
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The above table showed that 88.5% cases showed TTF1 positivity 
which were diagnosed as adenocarcinoma.. It was positive in 11.5% cases (3 
cases) which were further evaluated with neuroendocrine markers and 
diagnosed as small cell carcinoma. Among the 50 cases accounting 4 cases for 
16.7% cases showed TTF1 negativity which were further evaluated with 
neuroendocrine markers and diagnosed as small cell carcinoma. So it was 
inferred that in small cell carcinoma TTF1 can show positive expression or it 
may be negative. So TTF1 was not useful in separating small cell carcinoma 
from adenocarcinoma. 
 For table 15 it was found that among the 26 TTF1 positive cases 88.5% 
(23 cases) of cases were adenocarcinoma and 11.5 cases were small cell 
carcinoma. 
TABLE: 16 : FREQUENCY OF NAPSIN A EXPRESSION IN LUNG 
CANCERS 
NAPSIN Frequency Percent 
NEGATIVE 27 54.0 
POSITIVE 23 46.0 
Total 50 100.0 
 
 
         CHART - 16   
54%
46%
NEGATIVE
POSITIVE
                     TABLE - 16 
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From the above and chart-16 it was inferred that Napsin A was positive 
in 46% of cases which accounts for 23 cases and it was negative in 54% of 
cases which accounts for 27 cases. 
 
TABLE: 17 : FREQUENCY OF NAPSIN A EXPRESSION IN 
DIFFERENT SUBTYPES OF LUNG CANCER 
 
 NAPSIN Total 
NEGATIVE POSITIVE 
Diagnosis 
ADCC 
Count 0 23 23 
% within NAPSIN 0.0% 100.0% 46.0% 
SCC 
Count 7 0 7 
% within NAPSIN 25.9% 0.0% 14.0% 
SQCC 
Count 20 0 20 
% within NAPSIN 74.1% 0.0% 40.0% 
Total 
Count 27 23 50 
% within NAPSIN 100.0% 100.0% 100.0% 
Pearson Chi-Square=50.000** p<0.001 
 
 
 
TABLE - 17 
59 
 
 
 
 
From the above table it was inferred that 100% of cases that is all cases 
that showing napsin a positivity was adenocarcinoma. It was completely 
negative in squamous and small cell carcinoma. So napsin is considered as a 
specific marker for adenocarcinoma.  
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TABLE: 18:  COMPARISON OF TTF1 AND NAPSIN A IN LUNG 
CANCERS 
 TTF NAPSIN Total 
NEGATIVE POSITIVE NEGATIVE POSITIVE 
Diagnosis 
SQCC 
Count 20 0 20 0 20 
%  100.0% 0.0% 100.0% 0.0% 40.0% 
SCC 
Count 4 3 7 0 7 
%  57.1% 42.9% 100.0% 0.0% 14.0% 
ADCC 
Count 0 23 0 23 23 
%  0.0% 100.0% 0.0% 100.0% 46.0% 
Total 
Count 24 26 27 23 50 
%  48.0% 52.0% 54.0% 46.0% 100.0% 
 
 
From the above table it was inferred that TTF1 was positive in 
adenocarcinomas and in some small cell carcinomas. But it was invariably 
negative in squamous cell carcinomas. So with TTF1 we cannot distinguish 
adenocarcinoma from small cell carcinomas. Because 42.8% of  small cell 
carcinoma cases were positive for TTF1. So almost half of the small cell 
carcinomas were were TTF1 positive. 
Napsin A was positive in all adenocarcinomas and invariably negative in 
almost all cases of small cell carcinomas and squamous cell carcinomas. So 
napsin A can be used as a specific marker for distinguishing adenocarcinoma 
TABLE -18 
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from small cell carcinomas. With the Napsin A positivity we can exclude small 
cell carcinoma. So Napsin A can be used as exclusion marker for small cell 
carcinoma. 
TABLE: 19: CORRELATION OF HISTOPATHOLOGICAL 
DIAGNOSIS WITH IHC PROVEN FINAL DIAGNOSIS 
 
 Diagnosis Total 
ADCC SCC SQCC 
HPE_DIAGN
OSIS 
Adenocarcinoma 
Count 9 0 1 10 
% within 
Diagnosis 
39.1% 0.0% 5.0% 20.0% 
Non Small cell 
Lung Carcinoma 
Count 11 0 5 16 
% within 
Diagnosis 
47.8% 0.0% 25.0% 32.0% 
Positive for 
malignancy 
Count 3 5 7 15 
% within 
Diagnosis 
13.0% 71.4% 35.0% 30.0% 
Small cell 
carcinoma 
Count 0 2 1 3 
% within 
Diagnosis 
0.0% 28.6% 5.0% 6.0% 
Squamous Cell 
carcinoma 
Count 0 0 6 6 
% within 
Diagnosis 
0.0% 0.0% 30.0% 12.0% 
Total 
Count 23 7 20 50 
% within 
Diagnosis 
100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=34.938** p<0.001 
 
TABLE - 19 
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CHART - 19 
 From the above table it was inferred that among the 10 cases diagnosed 
as adenocarcinoma based on morphology alone, 9 cases were proven by IHC as 
adenocarcinoma. One case was turned to be squamous cell carcinoma on IHC. 
 It was found that 3 cases were diagnosed as small cell carcinoma based 
on morphology alone. Out of these three cases 2 were confirmed with IHC as 
small cell carcinoma. One case turned to be squamous cell carcinoma on IHC. 
 It was found that 6 cases were diagnosed as squamous cell carcinoma 
based on morphology. All cases were confirmed by IHC as squamous cell 
carcinoma.  
 Among the 50 cases further subtyping could not be done in 31 cases by 
morphological examination alone. They were subjected to IHC. Out of that 31 
cases 14 were found to be positive for adenocarcinoma markers, 5 were found 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ADCC
SCC
SQCC
39%
0% 5%
48%
25%
13%
71%
35%
0%
29%
5%
0%
30%
Squamous Cell carcinoma
Small cell carcinoma
Positive for malignancy
Non Small cell Lung Carcinoma
Adenocarcinoma
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to be positive for small cell carcinoma markers and 12 were diagnosed as 
squamous cell carcinoma. 
TTF EXPRESSION IN ADENOCARCINOMA 
 Diagnosis Total 
ADCC OTHERS 
TTF 
POSITIVE 
Count 23 3 26 
% within diagnosis 100.0% 11.1% 52.0% 
NEGATIVE 
Count 0 24 24 
% within diagnosis 0.0% 88.9% 48.0% 
Total 
Count 23 27 50 
% within diagnosis 100.0% 100.0% 100.0% 
Pearson Chi-Square=39.316** P<0.001 
     
TABLE - 20 
 
Statistics Value 95% CI 
Sensitivity 100.00% 85.18% to 100.00% 
Specificity 88.89 % 70.84% to 97.65% 
Positive Likelihood Ratio 9.00 3.10 to 26.16 
Disease prevalence 46.00% (*) 31.81% to 60.68% 
Positive Predictive Value 88.46% (*) 72.51% to 95.70% 
Negative Predictive Value 100.00 % (*)   
CHART - 20 
 
From the above table it was inferred that sensitivity of TTF1 to 
adenocarcinoma was 100% and its specificity to adenocarcinoma was 88.86%. 
P value was <0.001. that is TTF1 expression in adenocarcinoma was 
statistically significant. 
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NAPSIN EXPRESSION IN ADENOCARCINOMA 
 
 Diagnosis Total 
ADCC OTHERS 
NAPSIN 
POSITIVE 
Count 23 0 23 
% within 
diagnosis 
100.0% 0.0% 46.0% 
NEGATIV
E 
 
Count 
 
0 
 
27 
 
27 
% within 
diagnosis 
0.0% 100.0% 54.0% 
TOTAL 
 
Count 
 
23 
 
27 
 
50 
% within 
Diagnosis 
100.0% 100.0% 100.0% 
Pearson Chi-Square=50.00** P<0.001 
 
 
TABLE - 21 
 
 
TABLE 21 (A)  
 
Statistic Value 95% CI 
Sensitivity 100.00% 85.18% to 100.00% 
Specificity 100.00 % 87.23% to 100.00% 
Disease prevalence 46.00% (*) 31.81% to 60.68% 
Positive Predictive Value 100.00% (*)  
Negative Predictive Value 100.00 % (*)  
65 
 
From the above table it was inferred that sensitivity of napsin A in 
adenocarcinoma was 100% and its specificity was 100%. P value is <0.001, 
that is napsin A expression in adenocarcinoma was statistically significant. 
TTF1 EXPRESSION IN SMALL CELL CARCINOMA 
 
TABLE - 22 
 
Statistic Value 95% CI 
Sensitivity 57.14% 18.41% to 90.10% 
Specificity 53.49 % 37.65% to 68.82% 
Positive Likelihood Ratio 1.23 0.60 to 2.52 
Negative Likelihood Ratio 0.80 0.33 to 1.97 
Disease prevalence 14.00% (*) 5.82% to 26.74% 
Positive Predictive Value 16.67% (*) 8.89% to 29.06% 
Negative Predictive Value 88.46 % (*) 75.72% to 94.96% 
 
CHART - 22 
From the above table it was inferred that TTF1 sensitivity for small cell 
carcinoma was 57.14% and its specificity was 53.9%.  
TTF1 SCC Others 
Negative 4 20 
Positive 3 23 
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NAPSIN A  IN SMALL CELL CARCINOMA: 
 
TABLE  - 23 
 
 
 
 
 
 
 
 
 
TABLE – 23 (A)  
It was inferred from the above table that Napsin A sensitivity to 
excluding small cell carcinoma was 100% and its specificity to exclude small 
cell carcinoma was 52.49%. 
TTF EXPRESSION IN SQUAMOUS CELL CARCINOMA 
 
TABLE - 24 
Napsin SCC Others 
Negative 7 20 
Positive 0 23 
Statistic Value 95% CI 
Sensitivity 100.00% 59.04% to 100.00% 
Specificity 53.49 % 37.65% to 68.82% 
Positive Likelihood Ratio 2.15 1.56 to 2.96 
Negative Likelihood Ratio 0.00  
Disease prevalence 14.00% (*) 5.82% to 26.74% 
Positive Predictive Value 25.93% (*) 20.26% to 32.54% 
Negative Predictive Value 100.00 % (*)  
TTF1 SQCC Others 
Negative 20 4 
Positive 0 26 
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Statistic Value 95% CI 
Sensitivity 100.00% 83.16% to 100.00% 
Specificity 86.67 % 69.28% to 96.24% 
Positive Likelihood Ratio 7.50 3.01 to 18.68 
Negative Likelihood Ratio 0.00   
Disease prevalence 40.00% (*) 26.41% to 54.82% 
Positive Predictive Value 83.33% (*) 66.75% to 92.57% 
Negative Predictive Value 100.00 % (*)   
 
TABLE- 24A 
 
From the above table it was inferred that TTF 1 sensitivity to exclude 
squamous cell carcinoma was 100% and its specificity to exclude squamous 
cell carcinoma was 88.67%. 
NAPSIN A EXPRESSION IN SQUAMOUS CELL CARCINOMA 
 
TABLE – 25 
  
NAPSIN A SQCC Others 
Negative 20 7 
Positive 0 23 
68 
 
 
 
TABLE – 25 A 
 
From the above table it was inferred that napsin A  sensitivity to exclude 
squamous cell carcinoma was 100% and its specificity to exclude squamous 
cell carcinoma was 76.67%. 
COMPARISION OF NAPSIN A WITH TTF1 
  TTF  
  POSITIVE NEGATIVE Total 
NAPSIN 
POSITIVE 23 0 23 
NEGATIVE 3 24 27 
total  26 24 50 
Pearson Chi-Square=39.316** p<0.001 
 
TABLE - 27 
Statistic Value 95% CI 
Sensitivity 100.00% 83.16% to 100.00% 
Specificity 76.67 % 57.72% to 90.07% 
Positive Likelihood Ratio 4.29 2.24 to 8.20 
Negative Likelihood Ratio 0.00   
Disease prevalence 40.00% (*) 26.41% to 54.82% 
Positive Predictive Value 74.07% (*) 59.90% to 84.53% 
Negative Predictive Value 100.00 % (*)   
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Statistic Value 95% CI 
Sensitivity 88.46% 69.85% to 97.55% 
Specificity 100.00 % 85.75% to 100.00% 
Negative Likelihood Ratio 0.12 0.04 to 0.33 
Disease prevalence 52.00% (*) 37.42% to 66.34% 
Positive Predictive Value 100.00% (*)   
Negative Predictive Value 88.89 % (*) 73.40% to 95.87% 
 
TABLE – 27 A 
From the above table it was inferred that expression of napsin A in lung 
carcinoma is statistically significant. 
COMPARISON OF SENSITIVITY OF NAPSIN A WITH TTF1: 
SENSITIVITY TTF1 NAPSIN A 
AdCC 100% 100% 
SqCC 100% 100% 
SCC 57.1% 100% 
 
TABLE - 28 
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CHART – 28 
From the above table it was inferred that Napsin A has comparable 
sensitivity with TTF1 in the subtyping adenocarcinoma.  
It was inferred that sensitivity of Napsin A was comparable with TTF1 
in excluding squamous cell carcinoma. 
From the above table it was inferred  that napsin A is more sensitive 
(100%)  in excluding small cell carcinoma  than TTF1(57.1%) 
COMPARISON OF SPECIFICITY OF NAPSIN A WITH TTF1: 
SPECIFICITY TTF1 NAPSIN A 
AdCC 88% 100% 
SqCC 86% 76.6% 
SCC 53.48% 53.00% 
 
TABLE - 29 
AdCC
SqCC
SCC
100%
100%
57.10%
100% 100%
100%
TTF1 NAPSIN A
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CHART - 29 
From the above table it was inferred that specificity of napsin A in the 
subtyping of adenocarcinoma was higher(100%) than TTF1(88%). 
It was inferred that specificity of napsin A (76.60%) in excluding  
squamous cell carcinoma was lesser than  TTF1(86%). 
It was inferred that specificity of napsin A (53%) in excluding small cell 
carcinoma was comparable with that of TTF1 (53.48%). 
 
 
 
 
 
AdCC
SqCC
SCC
88%
86%
53.48%
100%
76.60%
53.00%
TTF1 NAPSIN A
DISCUSSION 
 
 
 
 
72 
 
DISCUSSION 
 The incidence of lung cancer is increasing in both developed and 
developing countries in the present era involving both males and female 
population. 
EPIDEMIOLOGY OF LUNG CANCERS IN GENERAL: 
In the present study, histomorphological study was done for 108 cases of 
lung cancers while immunohistochemical evaluation was done for a subset of 
50 cases. An attempt was made to check for the comparision of napsin A with 
TTF1 in all 50 cases including 23 cases of adenocarcinoma, 7 cases of small 
cell carcinoma and 20 cases of squamous cell carcinoma. 
Worldwide, histological profile of lung cancer patients is seen 
undergoing a changing trends and adenocarinoma had replaced squamous cell 
carcinoma as predominant histological subtype(94,95,96).  
However most of Indian studies still reports squamous cell carcinoma as 
a commonest type (97, 98, 99, 100), Viswanathan et al. (1962) (101), Shankar S et al. 
(1967) (102), Gularia et al (1971)(103), Malik et al. (1976)(104), Jindal and Behera 
et al.(1990)(99) from Chandigarh, Gupta RC et al. (1998)(105) and Bhattacharyya 
SK et al. (2010)(106) from India had reported squamous cell carcinoma as most 
dominant subtype.  
In our study, it was found that adenocarcinoma had a maximum 
incidence of 46%. The second most common was squamous cell carcinoma 
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accounting for 40%. Small cell carcinoma was the third most frequent subtype 
with relative percentage of 14% of the total cases.  
Our results were in concordance with recent Indian study by Mandal SK 
et al(2013)(107), Shankar et al (2014)(108) and Sundaram V et al(2014)(109), 
Mahendra Kumar et al (2016)(110) reporting adenocarcinoma as a commonest 
subtype.  
The peak incidence was noted in a age group of 51 to 60 years, the 
number of patients were 19 accounting for 38% of cases. It seems to have a 
least incidence in the age group of 41 to 50 years and 71 to 80 years with 
relative percentage of 14% in each age group.  
There is no increase in the incidence of lung cancers with increasing 
age. The tumor seems to be distributed along the age group in no specific 
pattern. 
 Adenocarcinoma was most common in the age group of 51 to 60 years 
accounting for 43.5%. It was least common in the age group of 71 to 80 years 
accounting for 8.7%  
 Squamous cell carcinoma was most common in the age group of 51 to 
60 years and 61 to 70 years with relative range of 35% in each group. It was 
least common in the age group of 41 to 50 years and 71 to 80 years with 
relative range of 15% in each group.  
 Small cell carcinoma was most common in the age group of 61 to 70 
years accounting for 42.9%, followed by second most commonly seen in 51 to 
60 years and 71 to 80 years with relative range of 28.6% in each age group.  
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Adenocarcinoma and squamous cell carcinoma was found to be 
commonly affect the age group of 51 to 60 years. Small cell carcinoma was 
found to be common in slightly older age group of 61 to 70 years.  
Our study results were in concordance with Pandhi N. et al (2015), 
Dubey N. et al (2015), Malik PS. et al (2013)(103), Koul PA.et al (2010), Sheikh 
S. et al(2010), Mahendra kumar. et al(2016)(110)reporting most common age 
group is 51-60 years.  
The incidence of lung cancers in males was found to be 70%. The 
incidence of lung cancers in female was found to be 30%. Male to female ratio 
was 2.3:1. P value is 0.141. So gender has significant value in lung cancers. 
It was found that adenocarcinoma was common among males with 
relative percentage of 60.9% as compared to 39.1% in females. 
 Squamous cell carcinoma was common among males with relative 
percentage of 70 % as compared to 30% in females. 
 Small cell carcinoma was found to be exclusively occurred only in 
males with relative percentage of 100.0%. 
  Our results were in concordance with Pandhi N. et al(2015), Dubey N. et 
al(2015), Malik PS. et al(2013)(103), Koul PA. et al(2010), Sheikh S. et 
al(2010), Mahendra kumar. et al(2016)(110), Baburao A. et al(2015), Sundaram 
V. et al(2014) (109), Mandal SK. et al(2013)(107), Bhaskarpillai B .et al(2012), 
Bhattacharyya et al (2010)(106), Rawat J et al(2009), Khan et al(2006), Prasad 
R.et al(2004) reporting that lung cancers were most commonly occurs in males. 
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Lung cancers found to be occurring more commonly in Right lobe with 
relative percentage of 56% followed by left lobe with little less frequency of 
44%. 
Our results were not in concordance with Mahendra kumar et al (2016) 
(110) reporting that lung cancers were common in right lobe. 
 Present study Mahendrakumar et al 
Right lobe 56% 45% 
Left lobe 44% 50% 
Bilateral - 5% 
 
The lung cancers seems to be predominant in upper lobe with relatively 
higher percentage of 66%, followed by lower lobes found to be involved in 
24% of cases with least common in middle lobe with least percentage of 10%. 
Most of the patients (26%) presented with the symptom of cough 
followed by chest pain in 20% of patients, followed by 18% of patients with 
dyspnoea, 18% with hemoptysis and 18% of patients presented with no specific 
symptoms. 
This is in concordance with the Mahendra kumar et al(2016)(106) 
reporting that most common presenting symptom is cough followed by chest 
pain. 
In lung adenocarcinoma cough followed by chest pain was found to be 
commonest presentation with relative percentage of 26.1% and 21.7% 
respectively. 
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Among the squamous cell carcinoma patients, Dyspnoea is the 
commonest presenting complaints with 25% relative percentage. 
Among the small cell carcinoma patients cough is the predominant 
symptoms with relative percentage of 57.1%. 
Lung cancers were common in smokers with 62% and 38% of non 
smokers developed lung cancers. 
This is in concordance with Mahendra kumar et al (2016) (101) reporting 
that lung cancers were common in smokers than non smokers. 
 Present study Mahendra kumar et al 
Smoker 62% 81.8% 
Non smoker 38% 18.2% 
 
Adenocarcinoma seems to be commonly occurs in non smokers with 
relative percentage of 52.2% in contrast to 47.8% in smokers.  
Squamous cell carcinoma and small cell carcinoma seems to be common 
in smokers with relative percentage of 65% and 100.0% respectively. Small 
cell carcinoma was found to be occur exclusively only in smokers. 
Most common image findings in lung cancers was found to be lung 
mass with relatively highest percentage of 54% followed by collapse with 24% 
followed by consolidation with 16% and least common finding was pleural 
effusion with relative frequency of 6%. 
Because of switch from non filtered to filtered cigarettes and altered 
inhalational depth, there is shift in the incidence of squamous cell carcinoma to 
adenocarcinoma (101) 
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DESCRIPTIVE STUDY OF LUNG CANCERS: 
Ours is a descriptive study, including a 1 year period from 2016 to 2017. 
The caseswere collected in both prospective and retrospective ways. The study 
is hospital based; hence it does not reflect the true incidence and prevalence in 
the community. Follow up was not available and not analysed. Of the 
 cases reported in our study, 50 cases were chosen randomly. 
ADENOCARCINOMA: 
Of the 50 cases selected for this study, adenocarcinoma constituted about 23 
cases, which was 46% of total. This is in concordance with Krishnamoorthy et 
al (120), Mahendra kumar et al (2016)(101) reporting that most common histology 
was adenocarcinoma accounting for 42.6% and 40.9% respectively. 
Present study 46% 
Krishnamoorthy et al 42.6% 
Mahendra kumar et al 40.9% 
 
 Adenocarcinoma was most common in the age group of 51-60 years 
accounting for about 43.5% of all cases in this age group. The youngest 
being 40 years and the oldest being 77 years.This is in concordance with 
reporting that adenocarcinoma  
 The total male patients in our study was 35, the number of females was 
15. Thus the calculated male : female ratio was 2.3: 1.  
 Among the adenocarcinoma, male patients were14, number of females 
was 9. Thus the calculated male female ratio was 1.5:1. But according to 
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WHO adenocarcinoma comprises 28% in men and 42% cases in women. 
There is slight female preponderance(121). 
 The most common presentation in lung adenocarcinoma patients was 
cough followed by chest pain. This is in concordance with that inferred 
in WHO. 
 Adenocarcinoma seems to be commonly occurs in non smokers with 
relative percentage of 52.2% (12 cases) in contrast to 47.8% in smokers 
(11 cases). This is in concordance with WHO estimates. The WHO 
estimates that 25% of lung cancer worldwide occurs in never smokers. 
These cancers occur more commonly in women and most are 
adenocarcinoma.(122) 
SQUAMOUS CELL CARCINOMA: 
 Of the 50 cases selected for this study, squamous cell carcinoma 
constituted about 20 cases, which was 40% of total. This is in concordance 
with Mahendra kumar et al (2016)(101) reporting that most common histology 
after adenocarcinoma was squamous cell carcinoma accounting for 32.7%. 
Present study 40% 
Mahendra kumar et al 32.7% 
 
 Squamous cell carcinoma was most common in the age group of 51-60 
and 61-70 years accounting for about 35% and 35% respectively of all 
cases in this age group. The youngest being 42 years and the oldest 
being 77 years.  
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 Among the adenocarcinoma male patients were14, number of females 
was 6 accounting for 70% males and 30% of cases were females. Thus 
the calculated male female ratio was 2.3:1. But according to WHO 
squamous cell carcinoma comprises 44% in men and 25% cases in 
women. There is slight male preponderance(121). 
 The most common presentation in lung squamous cell carcinoma 
patients was cough followed by chest pain. This is in concordance with 
that inferred in WHO. 
 Squamous cell carcinoma seems to be commonly occurs in smokers 
with relative percentage of 65% (13 cases) in contrast to 35% in 
nonsmokers (7 cases). This is in concordance with WHO estimates.(122) 
 
SMALL CELL CARCINOMA: 
 Of the 50 cases selected for this study, small cell carcinoma 
constituted about 7 cases, which was 14% of total. This is in 
concordance with Mahendra kumar et al (2016)(101). 
 Small cell carcinoma was most common in the age group of 61 to 70 
years accounting for 42.9% (3 cases), followed by second most 
commonly seen in 51 to 60 years and 71 to 80 years with relative 
range of 28.6% in each age group. (2 cases).  This is in concordance 
with Vanita Noronha et al(2016)(123) reporting that most common age 
group is 50- 59 years. 
 Small cell carcinoma was found to be exclusively occurred only in 
males with relative percentage of 100.0%(7 / 7 cases). 
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 Among the small cell carcinoma patients cough is the predominant 
symptoms with relative percentage of 57.1%. 
 Small cell carcinoma was found to be occur exclusively only in 
smokers. 
 
IMMUNOHISTOCHEMISTRY IN LUNG CANCERS: 
 Immunohistochemistry is increasingly utilized to differentiate lung 
adenocarcinoma and squamous cell carcinoma. In this study we used TTF1, 
CK 5/6, P63 and neuroendocrine markers to subtype the lung cancers. By using 
this panel we lung cancers were subtyped. Napsin A marker expression was 
studied in 50 randomly selected cases which constituting adenocarcinoma, 
squamous cell carcinoma and small cell carcinoma. IHC was done in formalin 
fixed paraffin embedded sections. 
 
EXPRESSION OF TTF1 IN LUNG CANCERS: 
 TTF1 expression was located in the nucleus with no staining on the 
membrane and in the cytoplasm.  
 In the present study it was inferred that TTF1 was positive in totally 
52% of cases (26 cases) and negative in 48% (24 cases) of cases. 
  In this present study 88.5% cases showed TTF1 positivity which were 
diagnosed as adenocarcinoma..  
 It was positive in 11.5% cases (3 cases) which were further evaluated 
with neuroendocrine markers and diagnosed as small cell carcinoma.  
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 Among the 50 cases accounting 4 cases for 16.7% cases showed TTF1 
negativity which were further evaluated with neuroendocrine markers 
and diagnosed as small cell carcinoma. So it was inferred that in small 
cell carcinoma TTF1 can show positive expression or it may be 
negative.  
 So TTF1 was not useful in separating small cell carcinoma from 
adenocarcinoma. 
 TTF1 was found to be positive in adenocarcinomas and in few small cell 
carcinomas. However TTF1 was found to be uniformly negative in all 
cases of squamous cell carcinoma.  
 Its sensitivity and specificity to adenocarcinoma were 100% and 88.86% 
respectively. P value was <0.001. That is statistically significant. 
 This is in concordance with other studies conducted by Bradley M. 
Turner et al(2012) (50) and Zhang et al(2010)(2), Sanjay Mukhopadhyay et 
al(2011)(69), Lisa M Stoll et al(2010)(124) 
Study Sensitivity Specificity 
Present study 100% 88.86% 
Bradley M. Turner et al 64% 90% 
Zhang et al 84.4% 83.9% 
Sanjay Mukhopadhyay et al 80% 89% 
Lisa M. Stoll et al 81% 81% 
 
 From the present study it was inferred that TTF1 sensitivity for 
excluding small cell carcinoma was 57.14% and its specificity for 
excluding small cell carcinoma was 53.9%.  
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 From the present study it was inferred that TTF 1 sensitivity to 
excluding squamous cell carcinoma was 100% and its specificity to 
excluding squamous cell carcinoma was 88.67%. 
EXPRESSION OF NAPSIN A IN LUNG CACERS: 
 For Napsin A, only a granular cytoplasmic staining pattern was accepted 
as positive. 
 From the present study it was inferred that Napsin A was positive in 
46% of cases (23 cases) it was negative in 54% of cases (27 cases). 
 From the present study it was inferred that 100% of cases that is all 
cases that showing napsin a positivity was adenocarcinoma. It was 
completely negative in squamous and small cell carcinoma. So napsin is 
considered as a specific marker for adenocarcinoma.  
 Napsin A was positive in all adenocarcinomas and invariably negative in 
almost all cases of small cell carcinomas and squamous cell carcinomas. 
So napsin A can be used as a specific marker for distinguishing 
adenocarcinoma from small cell carcinomas. With the Napsin A 
positivity we can exclude small cell carcinoma. So Napsin A can be 
used as exclusion marker for small cell carcinoma. 
 From the above table it was inferred that sensitivity of napsin A in 
adenocarcinoma was 100% and its specificity was 100%. P value is 
<0.001, that is statistically significant. 
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 Comparison with other studies such as Bradley M. Turner et al(2012) (50) 
and Zhang et al(2010)(2), Sanjay Mukhopadhyay et al(2011)(69), Lisa M 
Stoll et al(2010)(124) 
Study Sensitivity Specificity 
Present study 100% 100% 
Bradley M. Turner et al 87% 97% 
Zhang et al 84.9% 93.8% 
Sanjay Mukhopadhyay et al 58% 100% 
Lisa M. Stoll et al 65% 96% 
 
 It was inferred  that Napsin A sensitivity to exclude small cell carcinoma 
was 100% and its specificity to exclude small cell carcinoma was 
52.49%. 
 It was inferred that napsin A sensitivity to exclude squamous cell 
carcinoma was 100% and its specificity to exclude squamous cell 
carcinoma was 76.67%. 
 
COMPARISON OF TTF1 AND NAPSIN A:  
ADENOCARCINOMA: 
 The expression of napsin A was significantly correlated with TTF1 in 
the lung adenocarcinoma. 
 The senstivity of TTF1 in identifying adenocarcinoma was 100%. The 
sensitivity of napsin A in identifying adenocarcinoma was 100%. So 
both these marker have similar sensitivity for adenocarcinoma. 
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 The specificity of TTF1 in identifying adenocarcinoma was 88%. The 
sensitivity of napsin A in identifying adenocarcinoma was 100%. So 
napsin A was found to be more specific for adenocarcinoma than TTF1. 
 Hence NAPSIN A IS AS SENSITIVE AS TTF1 & MORE SPECIFIC 
THAN TTF1 in the subtyping of lung adenocarcinoma. 
SQUAMOUS CELL CARCINOMA: 
 The expression of napsin A was significantly correlated with TTF1 
in the lung squamous cell carcinoma. 
 The senstivity of TTF1 in excluding squamous cell carcinoma was 
100%. The sensitivity of napsin A in excluding  squamous cell 
carcinoma was 100%. So both these marker have similar sensitivity 
for excluding squamous cell carcinoma. 
 The specificity of TTF1 in excluding squamous cell carcinoma was 
86%. The sensitivity of napsin A in excluding squamous cell 
carcinoma was 76.6%. So napsin A was found to be less specific for 
squamous carcinoma than TTF1. So with napsin A negativity alone 
we cannot diagnose squamous cell carcinoma.  
 Hence NAPSIN A IS AS SENSITIVE AS TTF1 & LESS SPECIFIC 
THAN TTF1 in the subtyping of lung squamous cell carcinoma. 
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SMALL CELL CARCINOMA: 
 The expression of napsin A was significantly correlated with TTF1 
in the lung small  cell carcinoma. 
 The senstivity of TTF1 in excluding small cell carcinoma was 
57.1%. The sensitivity of napsin A in excluding  small cell 
carcinoma was 100%. So napsin A was found to be more sensitive 
than TTF1 for excluding small cell carcinoma. 
 The specificity of TTF1 in excluding small cell carcinoma was 
53.48%. The sensitivity of napsin A in excluding small cell 
carcinoma was 53%. So both these marker have similar specificity 
for excluding small cell carcinoma 
 Hence NAPSIN A IS AS SPECIFIC AS TTF1 & MORE 
SENSITIVE THAN TTF1 in the subtyping of lung small cell 
carcinoma. 
This is in concordance with other studies: 
 Bradley M. Turner et al reported that Napsin A was more 
sensitive than TTF1 for primary lung adenocarcinoma(87% 
versus  64% : p valiue<0.001). Napsin Awas more specific than 
TTF1 for primary lung adenocarcinoma versus all metastatic 
tumour.(p value <0.001). 
 T Ueno et al(2003) reported that napsin A is as sensitive as TTF1 
and more specific than TTF1. 
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T Ueno et al Sensitivity Specificity 
TTF1 84.6% 76.7% 
Napsin A 84.6% 94.3% 
 
STRENGTH AND LIMITATIONS OF THE STUDY: 
STRENGTH OF THIS STUDY: 
 Study was done at a tertiary care hospital in south india 
 The clinicopathological aspects of lung cancers – their relative 
incidence, age distribution, sex predeliction, side and lobe 
involvement, risk factor like smoking has been enumerated and 
will be of value in estimating the same for a future population 
based study. 
 The expression of napsin A in various lung cancer subtypes has 
been studied in this study.And it is compared with TTF1, a well 
known marker used in lung cancer. 
LIMITATIONS OF THIS STUDY: 
 This study is hospital based, hence doesnot reflect the true 
incidence and prevalence in the community. 
 Due to the economical constraints, only limited number of 
cases has been studied. 
 In many case, due to inadequate material from small biopsy 
specimens, further subtyping could not be studied. 
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RECOMMENDATIONS: 
• New responsibility of pathologist is to preserve tissue for molecular 
studies. 
• Along with TTF1, napsin A should be included in the panel to increase 
the specificity and sensitivity. 
• IHC cocktail markers can be used which include one nuclear marker and 
one cytoplasmic marker. 
• EGFR expression should be included as a routine test for all NSCLC for 
better treatment options for the patients. 
THE DIAGNOSIS OF LUNG CANCER IN SMALL BIOPSIES 
SHOULD HAVE THE FOLLOWING STRUCTURE: 
• Pathologic diagnosis 
• Reporting of immunohistochemical and/or mucin stains  
• If appropriate, a comment about the differential diagnosis 
If material has been submitted for molecular testing, this should be 
stated in a comment, specifying which block or slide is optimal for 
testing. 
 
 
 
SUMMARY 
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SUMMARY 
 In the present study, histomorphological study and 
immunohistochemical evaluation was done for a subset of 50 cases. An 
attempt was made to check for the comparison of napsin A with TTF1 in 
all 50 cases. 
 Adenocarcinoma had a maximum incidence of 46%. Followed by  
squamous cell carcinoma accounting for 40% and small cell carcinoma 
accounting for  14% of the total cases. 
 The peak incidence was noted in a age group of 51 to 60 years. The 
tumor seems to be distributed along the age group in no specific pattern. 
 The incidence of lung cancers in males and females were 70% and 30 % 
respectively.  Male to female ratio was 2.3:1 
 Lung cancer was found to be more common in Right lobe with relative 
percentage of 56% followed by left lobe with little less frequency of 
44%. 
 The lung cancer seems to be predominant in upper lobe with relatively 
higher percentage of 66%. 
 Most common presenting symptom was cough followed by chest pain. 
 Lung cancers were common in smokers than non smaokers. The 
smokers will have two times the risk of developing lung cancers when 
compared to non smokers.  
 On imaging they were commonly diagnosed as lung mass. Occasionally 
they mimic collapse, consolidation. 
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 TTF1 is a nuclear marker for adenocarcinoma. Napsin A is a 
cytoplasmic marker for adencarcinoma. 
 TTF1 was found to be positive in all adenocarcinomas and in few small 
cell carcinomas. TTF1 was found to be consistently negative in all cases 
of squamous cell carcinoma. 
  TTF1  sensitivity and specificity to adenocarcinoma were 100% and 
88.86% 
 TTF1 sensitivity for excluding small cell carcinoma was 57.14% and its 
specificity for excluding small cell carcinoma was 53.9%.  
 TTF 1 sensitivity to excluding squamous cell carcinoma was 100% and 
its specificity to excluding squamous cell carcinoma was 88.67%. 
 Napsin A was positive in all adenocarcinomas and invariably negative in 
almost all cases of small cell carcinomas and squamous cell carcinomas. 
So napsin A can be used as a specific marker for distinguishing 
adenocarcinoma from small cell carcinomas. With the Napsin A 
positivity we can exclude small cell carcinoma.  
 Napsin A can be used as negative exclusion marker for small cell 
carcinoma. 
 The sensitivity of napsin A in adenocarcinoma was 100% and its 
specificity was 100%.  
 Napsin A sensitivity to exclude small cell carcinoma was 100% and its 
specificity to exclude small cell carcinoma was 52.49%. 
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 Napsin A sensitivity to exclude squamous cell carcinoma was 100% and 
its specificity to exclude squamous cell carcinoma was 76.67%.  
  NAPSIN A IS AS SENSITIVE AS TTF1 & MORE SPECIFIC THAN 
TTF1 in the subtyping of lung adenocarcinoma 
 NAPSIN A IS AS SENSITIVE AS TTF1 & LESS SPECIFIC THAN 
TTF1 in the subtyping of lung squamous cell carcinoma. 
  NAPSIN A IS AS SPECIFIC AS TTF1 & MORE SENSITIVE THAN 
TTF1 in the subtyping of lung small cell carcinoma. 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 Increase in the target specific chemotherapeutic therapies required futher 
subcategorisation of NSCLCs.IHC can be used to achieve a greater diagnostic 
sensitivity and specificity than cytomorphology alone. A combination f napsin 
A and TTF1 is useful in the distinction of primary lung adenocarcinoma from 
primary lung squamous cell carcinoma and primary lung small cell 
carcinoma.Lung adenocarcinoma will have the IHC profile of napsinA + ve/ 
TTF1 + ve ( or ) Napsin A +ve / TTF 1 – ve ; lung squamous cell carcinoma 
will have IHC profile of Napsin A –ve  / TTF1 –ve  ; lung small cell carcinoma 
will have IHC profile of Napsin A – ve / TTF1 +ve . The combined uise of 
napsin A and TTF1 increases the sensitivity and specificity of identifying the 
specific subtype. Since Napsin A is negative in all small cell carcinoma this 
stain may prove to be a useful exclusionary marker in distinguishing 
pulmonary small cell carcinomq from other poorly differentiated lung 
carcinoma with similar morphology especially those with concomitant TTF 1 
expression. 
COLOR PLATES 
 
 ADENOCARCINOMA: 
 
       
 
 
 
 
 
           
        
 
 
 
BX NO:3638/17:  (10X, H&E) 
Sheets of round to polygonal cells 
with moderate eosinophilic 
cytoplasm with round to oval 
pleomorphic hyperchromatic 
nuclei. 
  
IHC NO: 424/17: (   40X ) : 
TTF1 DIFFUSE STRONG 
POSITIVITY IN TUMOUR 
CELLS 
IHC NO:  424/17    (40 X) P63 DIFFUSE 
STRONG POSITIVITY 
IHC NO: 424/17: (40 X) DIFFUSE 
STRONG POSITIVITY 
 SQUAMOUS CELL CARCINOMA: 
 
        
 
 
 
 
 
    
 
 
 
BX NO: 740/17: (40X: H&E) nests and 
sheets of round to polygonal cells with 
moderate cytoplasm with round dark 
staining nuclei. 
IHC NO: 79/17: (40X) TTF1 NEGATIVE IN 
TUMOUR CELLS  
IHC NO: 79/17: (40 X) P63 POSITIVE IN 
TUMOUR CELLS 
IHC NO: 79/17:  (40 X)  NAPSIN A 
NEGATIVE IN TUMOUR CELLS 
 SMALL CELL CARCINOMA:   
      
 
 
      
 
  
BX NO : 6112/16: (H&E: 40X) sheets of 
round to oval pleomorphic cell with irregular 
round hyperchromatic nuclei. 
IHC NO: 616/16: ( 40X )  TTF1 
NEGATIVE IN TUMOUR CELLS. 
NAPSIN A NEGATIVE IN TUMOR CELLS P 63 NEGATIVE IN TUMOR CELLS 
CHROMOGRANIN DIFFUSE STRONG 
POSITIVE IN TUMOUR CELLS 
 SMALL CELL CARCINOMA: 
             
 
 
                      
      
     
  P63 NEGATIVE IN TUMOUR CELLS NAPSIN A NEGATIVE IN TUMOUR CELLS 
BX NO:  2430/17:  (40 X, H&E) Sheets 
of round to oval cells withscant 
cytoplasm dark staining nuclei 
IHC’: 312/17: (40 X) TTF1 POSITIVE IN 
TUMOUR CELLS 
CHROMOGRANIN DIFFUSE STONG 
POSITIVE IN TUMOUR CELLS 
ANNEXURES 
 
 
 
 
 
 
 
 ANNEXURE – 1 
 2015 WHO CLASSIFICATION OF LUNG EPITHELIAL TUMOURS:          
Adenocarcinoma                                                               
Lepidic adenocarcinomae                                                            
Acinar adenocarcinoma                                                     
Papillary adenocarcinoma                                                  
            Micropapillary adenocarcinomae        
Solid adenocarcinoma         
            Invasive mucinous adenocarcinomae       
            Mixed invasive mucinous and nonmucinous adenocarcinoma    
            Colloid adenocarcinoma         
             Fetal adenocarcinoma         
             Enteric adenocarcinoma        
            Minimally invasive adenocarcinoma 
                 Nonmucinous / Mucinous          
  
 Preinvasive lesions 
             Atypical adenomatous hyperplasia        
             Adenocarcinoma in situe 
                    Nonmucinous  /  Mucinous        
   
 Squamous cell carcinoma         
             Keratinizing squamous cell carcinoma      
             Nonkeratinizing squamous cell carcinoma      
             Basaloid squamous cell carcinomae        
Preinvasive lesion 
             Squamous cell carcinoma in situ        
Neuroendocrine tumors: 
             Small cell carcinoma         
                    Combined small cell carcinoma       
              Large cell neuroendocrine carcinoma       
                    Combined large cell NEC    
              Carcinoid tumors 
                     Typical carcinoid tumor        
                     Atypical carcinoid tumor        
             Preinvasive lesion 
                    Diffuse idiopathic pulmonary NE hyperplasia             
  Large cell carcinoma         
  Adenosquamous carcinoma         
              
  Sarcomatoid carcinomas 
            
  Pleomorphic carcinoma                                                                           
            
  Spindle cell carcinoma       
              
 Giant cell carcinoma                                                                                 
 
  Carcinosarcoma 
                      
 Pulmonary blastoma           
    
Other and Unclassified carcinomas 
          
Lymphoepithelioma-like carcinoma       
         
 NUT carcinoma                    
 
Salivary gland-type tumors 
         
Mucoepidermoid carcinoma        
        
 Adenoid cystic carcinoma       
         
 Epithelial-myoepithelial carcinoma       
        
 Pleomorphic adenoma         
 
Papillomas 
 Squamous cell papilloma         
             
Exophytic /  Inverted         
        
Glandular papilloma        
        
Mixed squamous and glandular papilloma      
 
Adenomas 
         
Sclerosing pneumocytomae        
         
Alveolar adenoma         
       
  Papillary adenoma        
        
 Mucinous cystadenoma         
        
 Mucous gland adenoma         
 
 
 
  
ANNEXURE – 2 
 
 
 
PROFORMA: 
 
 
CASE NO:         
 
BIOPSY NO: 
 
NAME:         
 
AGE: 
 
SEX:          
 
IP NO: 
 
CLINICAL DIAGNOSIS: 
 
SYMPTOMS: 
 
RISK FACTORS IF ANY: 
 
CT/MRI FINDINGS: 
 
FOB FINDINGS: 
 
PROCEDURE DONE: 
 
CYTOLOGY REPORT: 
 
MICROSCOPY: 
 
HISTOLOGICAL TYPE: 
 
IHC PROFILE: 
 
 
 
 
  
                                                          INFORMATION SHEET 
 
Title :  “Comparision Of Napsin A Versus Thyroid Transcription Factor-1 In The Typing 
Of Lung Carcinoma’’  
 
Your specimen has been accepted. 
 We are conducting a study to compare utility of Napsin A with TTF-1 in the typing of 
lung carcinoma, Rajiv Gandhi government general hospital, Chennai and for that your 
specimen may be valuable to us. 
 The purpose of this study is to  compare the Utilization of Napsin A with TTF-1 in the 
typing of Lung carcinoma. 
 We are selecting certain patients with lung carcinoma and we will be using your 
specimen to perform extra tests and special studies which in any way do not affect 
your final report or management. 
 The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management or 
treatment. 
 
 
Signature of investigator     Signature of participant 
 
Date:  
 
 
 
 
  
INFORMED CONSENT FORM 
 
Title of the study   : “Comparision  Of  Napsin A Versus  Thyroid Transcription Factor -1 In The 
Typing Of Lung   Carcinoma’’  
Name of the Participant : 
Name of the Principal (Co-Investigator) :  
Name of the Institution : Institute of Pathology, Madras Medical College. 
Name and address of the sponsor / agency (ies) (if any):  
Documentation of the informed consent 
 
I _____________________________ have read the information in this form (or it has been read to me). I 
was free to ask any questions and they have been answered. I am over 18 years of age and, exercising my 
free power of choice, hereby give my consent to be included as a participant in 
“Study of Comparision  Of  Napsin A Versus  Thyroid Transcription Factor -1 In The Typing Of 
Lung   Carcinoma’’   
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study in which the lung biopsy will be subjected to  
histopathological examination and special tests. 
4. I have been explained about my rights and responsibilities by the investigator. I have the right to 
withdraw from the study at any time. 
5. I hereby give permission to the investigators to release the information obtained from me as result of 
participation in this study to the sponsors, regulatory authorities, Govt. agencies, and IEC. I understand 
that they are publicly presented. 
6. I have understand that my identity will be kept confidential if my data are publicly presented 
7. I have had my questions answered to my satisfaction. 
8. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. By signing this 
consent form I attest that the information given in this document has been clearly explained to me and 
understood by me, I will be given a copy of this consent document. 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
Name _________________________ Signature_________________ Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature_________________ Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________ Date________________ 
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